Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) EBIT Margin (2018 - 2025)

Cue Biopharma (CUE) has disclosed EBIT Margin for 8 consecutive years, with 242.62% as the latest value for Q4 2025.

  • Quarterly EBIT Margin fell 123746.0% to 242.62% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 36.47% through Dec 2025, up 5548.0% year-over-year, with the annual reading at 19.96% for FY2025, 7201.0% up from the prior year.
  • EBIT Margin hit 242.62% in Q4 2025 for Cue Biopharma, up from 353.42% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 1480.08% in Q4 2024 to a low of 50346.15% in Q2 2022.
  • Historically, EBIT Margin has averaged 4616.6% across 5 years, with a median of 640.78% in 2023.
  • Biggest five-year swings in EBIT Margin: crashed -4996999bps in 2022 and later skyrocketed 4936808bps in 2023.
  • Year by year, EBIT Margin stood at 95.62% in 2021, then tumbled by -10196bps to 9845.03% in 2022, then surged by 92bps to 759.58% in 2023, then skyrocketed by 295bps to 1480.08% in 2024, then tumbled by -84bps to 242.62% in 2025.
  • Business Quant data shows EBIT Margin for CUE at 242.62% in Q4 2025, 353.42% in Q3 2025, and 292.32% in Q2 2025.